intraoperative intensive vs conventional glucose control on perioperative outcomes in major non-cardiac surgery remain unknown.
Another factor influencing the surgical stress response and inflammation, and thus postoperative outcomes, is anaesthetic management. 16 For example, deep anaesthesia may be associated with adverse outcomes including mortality. Lindholm and colleagues 17 showed that duration at deep anaesthetic levels [bispectral index (BIS),45] was significantly related to 1 and 2 yr mortality, and that non-survivors spent more time at deep BIS levels than the survivors (hazard ratio of 1.13 h 21 ). In a cohort of adults having non-cardiac surgery under general anaesthesia, lower BIS levels were independently associated with higher mortality. 18 In this study, 18 as in the Lindholm and colleagues' trial, 17 most deaths were attributed to either cancer or cardiovascular aetiologies, the pathogenesis of which has been well linked to inflammation. 19 -21 The authors thus postulated that prolonged deep anaesthesia increases mortality by aggravating the inflammatory response to surgery. In support of that theory, a pilot study in orthopaedic joint replacement patients demonstrated that patients who received BISguided anaesthesia (target 45-60) showed a reduced postoperative inflammatory CRP response compared with deeper standard clinical practice. 22 Evidence thus suggests that steroid administration, tight glucose control, and avoidance of deep anaesthesia may decrease perioperative morbidity by ameliorating the inflammatory response to surgery. Using a three-way factorial design, we thus tested the primary hypotheses that major perioperative morbidity is reduced by: (i) low-dose dexamethasone, (ii) intensive intraoperative glucose control, and (iii) lighter anaesthesia. We also tested the secondary hypotheses that each intervention reduces circulating concentrations of the inflammatory marker hsCRP and all-cause 1 yr mortality.
Methods
The study was conducted with approval of the Cleveland Clinic Institutional Review Board and written informed consent was obtained from all patients. Enrolment extended from March 2007 through July 2010.
The methods of DeLiT trial are presented in detail elsewhere. 23 Briefly, we enrolled patients having elective major non-cardiac surgery under general anaesthesia. The study was initially restricted to patients ≥50 yr old having open major vascular surgery, but was expanded to include patients ≥40 yr because of slow initial enrolment. We excluded patients who received i.v. or oral steroid therapy within 30 days, had any contraindications to the proposed interventions, had an ASA Physical Status (ASA PS) .IV, or were not fluent in English. Randomization codes were generated by the PLAN procedure in SAS statistical software, and implemented using a concealed-allocation web-based system that was accessed by research physicians just before the planned surgery. Clinicians were blinded to the dexamethasone but not to the glucose control or depth of anaesthesia interventions. However, patients and investigators responsible for assessing postoperative outcomes were fully blinded. Our primary outcome was a collapsed composite endpoint (any vs none) defined as the occurrence of at least one of the 15 major complications before hospital discharge, including sepsis, severe surgical site infection, myocardial infarction, heart failure, stroke, unstable ventricular arrhythmias, pulmonary embolism, pneumonia, respiratory failure, dialysis dependent renal failure, large pleural or peritoneal effusions, major bleeding, major wound and surgical site healing complications, vascular graft thrombosis, and 30 day mortality.
Blood samples were collected before incision and on the first and second postoperative days, and were centrifuged in the cold at 3000g; plasma and serum were separated and stored in a freezer at 2808C. High-sensitivity CRP (hsCRP) was measured by an immunoturbidimetric method on an Abbott Architect ci8200 auto analyser (Abbott Laboratories, Abbott Park, IL, USA) using Kamiya hsCRP reagents (Kamiya Biomedical Co., Seattle, WA, USA). Each set of samples was accompanied by at least one set of bi-level plasma controls. These controls have a recorded inter-and intra-day coefficient of variation of ,5%. The hsCRP results are reported in milligram per litre.
One-year mortality data were obtained from electronic medical records, the United States Social Security Index, or both and confirmed by direct telephone contact with patient/family.
Statistical analysis
Balance on baseline characteristics among the randomized groups was assessed separately for each intervention. Any variable with a standardized difference .0.3 in the absolute value was adjusted for when comparing intervention groups on outcomes. Analysis was intent-to-treat.
Primary outcome
We assessed the effects of all three interventions on the incidence of any major morbidity in a single logistic regression model. In the absence of a three-way or any two-way interactions among the interventions (all P.0.10), each main effect was tested by collapsing over the other interventions, after adjusting for imbalanced baseline variables. In addition, the effect of each intervention on each individual major complication component was assessed in separate logistic regressions (one for each component; the significance criterion was 0.0039/16¼0.00024, a Bonferroni correction for 16 components, with interim-analysis a of 0.0039).
One year mortality
We assessed the effects of all three interventions on the incidence of 1 yr all-cause mortality in a single logistic regression model, adjusting for imbalanced baseline variables.
C-reactive protein
The effects of each randomized intervention on hsCRP and maximum postoperative change in hsCRP within two postoperative days from baseline were evaluated using linear regression.
Interim analyses
This trial followed a group sequential design in which four interim analyses were planned, using the gamma spending function 25 with gamma values of 23 and 0 for efficacy and futility, respectively. Results for the final analysis presented here used interim-adjusted confidence intervals (CIs) incorporating the z-statistic efficacy boundary of 2.884 for the n¼381 patients included.
23
Unless Bonferroni-corrected, all reported CIs use the interim-adjusted z-statistic of 2.884, corresponding to an a of 0.0039, and thus technically have 99.6% confidence. Throughout, we refer to them as '95% CIs' to indicate that the significance level was controlled at 5% for each hypothesis in the group sequential design.
Sample size considerations
The incidence of our primary outcome ranged from 15% to 19% from 2000 to 2003 in our institution's vascular surgery registry. However, we believed that these retrospective data underestimated the true incidence and expected a somewhat higher incidence because we planned to monitor the outcomes more closely than is done for retrospective data registeries. We thus assumed the true incidence to be 25% in the group receiving none of the three interventions. A maximum of 970 total patients were required to have 90% power at the 0.05 significance level to detect a 40% relative reduction on the primary outcome for the most effective intervention (whichever of the three), assuming effects of 20% and 10% for the other two interventions. If only one of the three factors had any effect, we had 90% power to detect a slightly narrower 37% relative reduction. R 2.12.0 software (R Foundation for Statistical Computing, Vienna, Austria), SAS 9.2 software (SAS Institute, Cary, NC, USA), and East 5 software (Cytel, Inc., Cambridge, MA, USA) were used.
Results
The intervention groups for the randomized patients (Fig. 1) included in the final analysis were well balanced on most patient characteristics and baseline characteristics ( Table 1) . Only the presence of a history of coronary artery disease was imbalanced (standardized difference.0.3 in absolute value), and was therefore adjusted for in all analyses.
At the time of the first interim analysis (n¼242), the Executive Committee decided to move the next analysis up from 50% to 37.5% of the planned enrolment based largely on logistical constraints but also with some concern for the possible futility of the interventions. The second analysis was conducted at n¼364 (37.7% of planned maximum of 970); 17 additional patients were randomized, while outcomes data on the 364 were being collected and analysed. We thus report on all 381 randomized patients in this report.
The observed incidences of any major morbidity were very close to 20% for each randomized group. No three-way (P¼0.70) or two-way interactions (all P.0.52) among the interventions were found on the primary outcome. Therefore, each of the three main effects was assessed marginally by collapsing over the other interventions in a single linear regression model adjusting for the history of coronary artery disease.
None of the interventions had an effect on major morbidity (all P-values .0.86, Table 2 and Fig. 2 ). At this second (and final) analysis (n¼381), the group sequential efficacy and futility boundaries for the primary outcome were P≤0.0039 and P.0.7912, respectively. Since each of the three interventions crossed the futility boundary, a recommendation was made to stop the trial (Fig. 3) . In a sensitivity analysis, we also assessed the treatment effects using a more stringent criterion for baseline imbalance (a standardized difference of 0.20, thus adjusting for ASA status, type of surgery, and history of congestive heart failure in addition to coronary artery disease); results were nearly identical to our main analyses and reached the same conclusions.
The study was not powered to assess effects on the individual outcomes of the composite, as evidenced in Table 2 by the wide CIs (and some inestimable effects due to low incidence) for the individual components. No effect on 1 yr allcause mortality was found for any of the three randomized interventions (all P-values .0.80, Table 2 ).
Glucose control intervention
Our glucose control intervention had no effect on the primary outcome of major morbidity, with odds ratio (95% CI) of 0. 
Anaesthetic depth intervention
Our anaesthetic depth intervention had no effect on the primary outcome of major morbidity, with odds ratio (95% CI) of 1.0 (0.49, 2.2), P¼0.90. The overall median of individual 
Dexamethasone intervention and CRP analysis
Our steroid intervention also had no effect on the primary outcome of major morbidity, with odds ratio (95% CI) of 0.96 (0.45, 2.0), P¼0.87. The mean hsCRP levels at POD1 and POD2 (Table 3 , Fig. 6A ), and the mean changes in CRP from baseline (Table 3 , Fig. 6B ) were significantly lower in patients given dexamethasone than placebo (all P-values ,0.001); all groups had similar median hsCRP at baseline. Neither the intensive vs conventional glucose control nor the light vs deep anaesthetic depth interventions affected either mean postoperative hsCRP or mean change in hsCRP (smallest P-value was 0.56). However, after adjusting for the three interventions and history of coronary artery disease, change in hsCRP from baseline to the maximum value observed on POD1 and 2 was associated with a slight increase in major morbidity (P¼0.002), with an estimated odds ratios of 1.06 (95% CI: 1.0, 1.12) for a 10 mg litre 21 increase in the change in hsCRP (Fig. 6C ).
Discussion
It is well established that surgery produces an inflammatory response that is proportionate to tissue injury. 1 2 Our results are consistent in that major surgery provoked an intense inflammatory response, as characterized by a roughly 30-fold elevation in plasma hsCRP concentrations. Many studies have examined preoperative levels of hsCRP in a variety of non-cardiac surgical populations, 26 -28 but few have quantified the inflammatory response to non-cardiac surgery per se. 29 30 Amar and colleagues 29 reported a four-to10-fold increase in hsCRP on the first postoperative day in 195 patients undergoing thoracic non-cardiac surgery. We extend this work by showing that the change in hsCRP from baseline to the maximum value observed on the first and second postoperative days is associated with major postoperative morbidity which corroborates the findings of Amar and colleagues 29 and Kouvelos and colleagues. 30 It is also well established that perioperative steroid administration blunts inflammation. 8 9 31 As might thus be expected, steroids significantly ameliorated the hsCRP response to tissue injury. Surprisingly, though, steroid-induced amelioration of the inflammatory response to surgery did not reduce postoperative complications. Large-dose steroids have been shown to improve postoperative outcomes in patients undergoing cardiac (n¼235) or colorectal (n¼20) surgery. 8 32 However, clinicians were understandably concerned about potential side-effects of such large doses. 6 Subsequent work by Kilger and colleagues 31 (n¼91) suggested that much smaller doses-which are presumably safer-are also effective. The dose we chose is similar to that used by Kilger and colleagues, 31 although we used a total of 14 mg of dexamethasone rather than hydrocortisone. The dose is also similar to Bisgaard and colleagues 9 who found that 8 mg of dexamethasone given i.v. to patients (n¼88) before their laparoscopic cholecystectomy reduced CRP concentrations and improved postoperative pain, fatigue, nausea and vomiting, and faster return to recreational activities. Steroid doses similar to the one we tested improved postoperative fatigue and duration of convalescence, 9 whereas we detected no reduction in a composite of serious complications. It remains possible that a larger dose or a different kind of steroid might have been more effective; 33 this argument is supported by the fact that while the typical CRP response to surgery was ameliorated in our patients, the increase was nonetheless substantial in both groups. Our study is the largest to evaluate small-to-moderate-dose steroids in general surgical patients. Furthermore, enrolment was restricted to patients undergoing major surgery. And finally, most had substantial baseline co-morbidity ( 70% were ASA PS III or IV) and, in fact, about 20% of our patients experienced at least one component of our composite outcome. We thus had considerable power to detect steroid-induced benefit had there been one. Table 2 Effects of interventions on composite and individual major morbidities and 1 yr mortality (n¼381). Adjusting for the history of coronary artery disease. Composite components presented as number (%).*For the primary outcome (any major morbidity), the CIs were interim-adjusted using a z-statistic criterion of 2.884, corresponding to the interim analysis P-value boundary for efficacy (P≤0.0039); the futility boundary was P. In contrast to steroid administration-and somewhat surprisingly 10 -hsCRP was unchanged by tight glucose control.
But there are many mechanisms besides inflammatory modulation by which glucose control could reduce morbidity after major surgery. And as might thus be expected, benefit from tight glucose control has been demonstrated in various populations. 12 34 -36 In our surgical patients, though, no benefit (or harm) was detected. Our results are consistent with previous reports, 13 15 suggesting that tight intraoperative glucose control alone has little effect on the risk of serious complications after major non-cardiac surgery.
The blood glucose concentrations we targeted were those most commonly studied in critical care 12 we did not intervene for these patients until glucose went above the intervention threshold; but even without treatment, most never did. Thus, a larger difference in glucose concentrations could only be obtained by more aggressive treatment in patients assigned to intensive treatment. The difficulty with this approach-even assuming it improved outcome-is that tighter glucose control increases the risk of hypoglycaemia. 14 possibly because of the dynamic nature of our insulin infusion algorithm, the relatively frequent glucose concentration determinations (every 30 -60 min), and vigilance of the investigators and clinicians. 24 We, like most investigators, used the same target glucose concentrations for diabetic and non-diabetic patients. But in critical care patients, intensive glucose control appears to reduce mortality except in diabetics. 39 Similarly, Krinsley 40 reports that hyperglycaemia is associated with higher mortality in critical care patients without diabetes compared with those with diabetes. Furthermore, Egi and colleagues 41 found that lower blood glucose concentrations were associated with increased mortality in diabetic critical care patients. Our study was underpowered to assess the interaction between intensive glucose control and diabetic status. A differential effect of tight glucose control in diabetic and non-diabetic patients thus remains possible-but would not change our overall conclusion that tight intraoperative glucose control does not reduce the risk of severe morbidity after major non-cardiac surgery. Randomized trials have suggested that BIS-guided anaesthesia speeds recovery, improves haemodynamic control, and reduces respiratory complications, nausea and vomiting, and the duration of hospitalization. 42 -44 Our expectation that light anaesthesia would reduce inflammation was largely based on a report by Kerssens and Sebel 22 who found that the CRP response to joint replacement surgery was moderated when anaesthesia was guided to a BIS target of 45 -60 rather than deeper hypnosis (regretfully, that study has not since appeared in a peer-reviewed 
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Odds ratio and CI* Impact on major morbidity Fig 2 Odds ratios of any major morbidity for each intervention, adjusting for history of coronary artery disease. *CIs were interim-adjusted using a z-statistic criterion of 2.884, corresponding to the P-value boundary for efficacy (P≤0.0039). journal). In distinct contrast, we found that hsCRP concentrations were similar in a large group of patients who were randomly assigned to light vs deep hypnosis. Perhaps unsurprisingly, we also found no difference in the incidence of major complications between the two groups. Thus, while maintaining a light hypnotic plane during anaesthesia appears to provide substantial benefits, 42 43 preventing major morbidity is not among them. , and maximum of POD1 and 2, by intervention; and (C) probability of postoperative composite morbidity (on logit scale to correspond to the logistic regression analysis) vs change in CRP from baseline to maximum (POD1, POD2).
As our three interventions did not result in a difference in the primary outcome, it is thus unsurprising that we also did not show any difference in 1 yr mortality. Long-term mortality outcome has not been well studied for tight glucose control or steroids perioperative interventions. On the other hand, many observational and retrospective studies have suggested an association between depth of anaesthesia and 1 yr mortality; 18 44 we were unable to show the same results in our randomized trial. That said, it should be noted that 1 yr mortality was a secondary outcome and our trial was not powered to detect a statistically significant difference among study groups. Although we had 90% power to detect a relative reduction ranging from 37% to 40% for the strongest of the three effects studied, smaller effects would clearly be important as well, and the study did not have sufficient power to detect them. While our results are very non-significant, the CIs for our estimated treatment effects are wide and theoretically consistent with either no effect or up to a doubling (or halving) of the incidence of complications. However, since our observed effects were so close to zero, conditional power results indicated an extremely low probability of finding a significant effect even if the trial would have continued to the maximum planned sample size (n¼970).
We did not have sufficient power to detect interactions among the interventions, which would have required a planned maximum sample size of 4000 patients. But given the absence of main effects, interactions would have been quite unexpected. In fact, the interaction P-values were very non-significant (three-way interaction P¼0.70, and most significant two-way interaction P¼0.52), such that there was very little evidence of any interactions in the observed data, and thus very little evidence that any of the interventions varied as a function of one another.
The ideal requirements for a composite outcome may not have been completely met in this study, that is, that components have equal clinical severity, similar incidence, and similar treatment effects. 45 46 However, the components of our composite had a similar incidence and were of roughly comparable clinical severity (Table 2) , although mortality is certainly worse than the others. Our composite is a minor modification of the composite outcome used by Brandstrup and colleagues 47 and Nisanevich and colleagues. 48 That said, the use of a composite adverse outcome indicator rather than independently evaluating specific complications likely reduces the chance of type 2 error. More importantly, using any single outcome may not capture the entire effect of any of our interventions or the complex disease processes. In summary, major non-cardiac surgery induces marked inflammation. Among our three interventions-dexamethasone, tight glucose control, and light anaesthesia-only dexamethasone reduced the inflammatory response to surgery, measured by hsCRP. However, we found no evidence that any of the studied interventions reduced the risk of major morbidity or 1 yr all-cause mortality.
